An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

Akane Yamamichi\textsuperscript{a,}\textsuperscript{d}, Toshihiro Kasama\textsuperscript{a}, Fumiharu Ohka\textsuperscript{a}, Hiromichi Suzuki\textsuperscript{a}, Akira Kato\textsuperscript{a}, Kazuya Motomura\textsuperscript{a}, Masaki Hirano\textsuperscript{a,}\textsuperscript{c}, Melissa Ranjit\textsuperscript{b}, Lushun Chalise\textsuperscript{b}, Michihiro Kurimoto\textsuperscript{b}, Goro Kondo\textsuperscript{b}, Kosuke Aoki\textsuperscript{a,}\textsuperscript{d}, Noriata Kaji\textsuperscript{a}, Manabu Tokeshi\textsuperscript{a}, Toshio Matsubara\textsuperscript{a}, Takeshi Senga\textsuperscript{a}, Mika K. Kaneko\textsuperscript{c}, Hidenori Suzuki\textsuperscript{b}, Masahito Hara\textsuperscript{a}, Toshihiko Wakabayashi\textsuperscript{a}, Yoshinobu Baba\textsuperscript{a}, Yukinari Kato\textsuperscript{a} and Atsushi Natsume\textsuperscript{a}

\textsuperscript{a}Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
\textsuperscript{b}Department of Applied Chemistry, Graduate School of Engineering, Nagoya University, Nagoya, Japan
\textsuperscript{c}Division of Applied Chemistry, Hokkaido University, Sapporo, Japan
\textsuperscript{d}Department of Neurosurgery, Mie University Graduate School of Medicine, Tsu, Japan

ABSTRACT

World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 \mu volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.

1. Introduction

Glioma accounts for approximately 30% of all of central nervous system (CNS) tumors in adults.[1] Gliomas are divided into World Health Organization (WHO) grades I–IV\textsuperscript{[2]}: grade IV glioma, namely glioblastoma (GBM), is the most malignant subtype with a median survival time of approximately 15 months despite extensive surgical resection and chemo-radiotherapy.\textsuperscript{[3,4]} Although grade II and III gliomas (lower grade gliomas, LGGs) are less aggressive than GBM, because of their infiltrative...
nature, complete surgical removal cannot be achieved. Pathologically, the surrounding marginal tissue is a complex mixture of normal white and gray matters, infiltrative tumor cells, and hyperplastic reactive glial cells. Moreover, in most cases, LGGs appear similar to the normal tissue without clear boundaries between the two. Such non-circumscribed tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual fatality.[5]

Recent comprehensive genetic studies in large cohorts of LGGs revealed that the isocitrate dehydrogenase 1 (IDH1) mutation was found in 69–80% of these gliomas.[6–8] The most significant of the IDH1 mutations in LGGs substitutes the amino acid residue 132 from arginine to histidine (R132H), accounting for 83–90% of IDH1 mutations.[9–11] While the wild-type IDH1 catalyzes the oxidative decarboxylation of isocitrate and produces alpha-ketoglutarate (alpha-KG) in the tricarboxylic acid cycle,[12] the mutant IDH1 converts alpha-KG further into 2-hydroxyglutarate, which, as an oncogenic metabolite, plays several crucial roles in the initiation of glioma.[13] More importantly, the IDH1 mutation is rarely found in other CNS tumors,[14] and regardless of their locations (i.e. in the tumor core or in the margin), and every tumor cell in an LGG harboring the mutation of IDH1 expresses the mutated IDH1.[6] These facts suggest that detection of the IDH1 mutation would enable clinicians to distinguish LGGs from other CNS tumors and to better delineate the ambiguous tumor margin from the normal brain. The IDH1 mutation is a potential biomarker; however, the only means of detecting this mutation in routine clinical practice thus far are direct sequencing[15] and immunohistochemistry with anti-IDHR132H antibody,[16] both of which are time-consuming and labor-intensive.

We previously constructed immuno-wall devices to enable rapid molecular analysis (manuscript in preparation). These immuno-wall structures were fabricated with a photo-polymerizing polymer placed inside of microchannels on a plastic chip. This device enables the analysis of molecular characteristics in under 15 min using only a small sample.

In this study, we developed a novel immuno-wall device to detect the IDH1-R132H mutation in glioma. We found high sensitivity for IDH1-R132H even in small amounts of tumor tissue.

2. Methodology

2.1. Ethics statement

This study was approved by the institutional review board at Nagoya University Hospital and complied with all provisions of the Declaration of Helsinki. Informed consent was obtained before the operation from all the patients.

2.2. Cell lines

U87 and immortalized normal human astrocytoma (NHA), expressing either mutated IDH1 (U87-IDH1-R132H, NHA-IDH1-R132H, respectively) or wild-type IDH1 (U87-wtIDH1, NHA-wtIDH1, respectively) were kindly donated by Dr Russell O. Pieper of the University of California, San Francisco, CA, USA. These cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St Louis, MO, USA), containing 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA), 100 units ml⁻¹ of penicillin and 100 μg ml⁻¹ of streptomycin (Thermo Fisher Scientific Inc.) at 37°C in a humidified atmosphere of 5% CO₂.

2.3. Intra-operative collection of tumor tissues

Fresh tumor samples, 5–10 mm in diameter, were collected intraoperatively from 10 patients whose tumors were resected at Nagoya University Hospital in 2015. The location of each sample was recorded stereotactically in an intraoperative navigation system (Brainlab, Munich, Germany). Each tumor tissue was dissected into three pieces for the immuno-wall assay, immunohistochemistry, and DNA sequencing.

2.4. Preparation of protein lysate

Cell pellets were mechanically broken down in RIPA buffer (Wako, Osaka, Japan), which contained protease inhibitor (Wako), and centrifuged at 15,000 rpm for 5 min at 4°C. Supernatants were collected and analyzed with the immuno-wall assay. In order to lyse the tumor tissues, the tissues were placed in 1.5 ml tubes containing 200 μl RIPA buffer, a protease inhibitor, and resin beads, which were then collectively ground using pestles from a sample-grinding kit (GE Healthcare, Little Chalfont, UK). The lysate was then centrifuged at 15,000 rpm for 5 min at 4°C and the supernatants were collected and analyzed. Approximately 100 μg of protein was extracted from 10⁵ cells.

2.5. Western blot analysis

Cell lysates were boiled at 100°C for 5 min in SDS sample buffer (New England Biolabs, Ipswich, MA, USA) containing 42 mM dithiothreitol (Cell Signaling Technologies, Danvers, MA, USA). Next, the samples (50 μg) were applied to each well and resolved on a 10% polyacrylamide gel (Bio-rad, Hercules, CA, USA). Proteins were transferred to a polyvinylidene difluoride membrane (GE Healthcare), blocked with 5% skim milk in phosphate-buffered saline (PBS) containing 0.1% Tween-20 for 1 h at room temperature, and incubated with HMab-2, Rcmab-1, and anti-β-actin (Sigma-Aldrich) for 60 min at room temperature. The
membrane was then washed, incubated with horseradish peroxidase-labeled secondary antibodies for 30 min at room temperature, and visualized using an enhanced chemiluminescence method.

2.6. Immuno-wall assay

The structure of the immuno-wall device is shown in Figure 1. Immuno-wall chips with 40 microchannels (1 mm width, 40 μm height and 8.5 mm length each) in a cyclic olefin polymer substrate were constructed using photolithography. The channel was filled with 6% azide-unit pendant water-soluble photopolymer (AWP; Toyo Gosei, Tokyo, Japan) and 10 mg ml⁻¹ streptavidin. UV light (313 nm, 20 mW cm⁻²) through slits in a photomask was used to immobilize the photoactive polymer in the center of the channels, before the uncured polymer was washed with PBS. (C, D) A biotinylated anti-R132H-IDH1 antibody (HMab-2), an anti-wild-type IDH1 antibody (RcMab-1), and a fluorescent DyLight650-conjugated goat anti-rat IgG antibody were used to label IDH1-R132H. Note that RcMab-1 is interacted with multiple numbers of DyLight 650-conjugated anti-rat IgGs.

Biotinylated HMab-2 (1 μl, 50 μg ml⁻¹) was injected into inlets, and incubated for 1 h. Microchannels were washed five times with washing buffer. The sample lysate (1.5 μl) was then injected into the inlet and incubated for 5 min followed by incubation of RcMab-1 (1 μl, 50 μg ml⁻¹) for 30 s. DyLight650-conjugated goat anti-rat IgG was applied. Finally, the fluorescence was measured and quantified using a fluorescence microscope with a CCD camera and ImageJ software (National Institute of Health, Bethesda, MD, USA).

2.7. Direct sequencing and pyrosequencing for IDH1 mutation

DNA was prepared using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The amount of DNA obtained from the tumor was sufficient for the subsequent genomic analyses. For IDH1 sequencing, a 129-bp fragment, spanning the sequence encoding the catalytic domain of IDH1, including codon 132, was amplified. We applied conventional polymerase chain reaction (PCR) for 35 cycles with denaturation at 95 °C for 30 s, annealing at 56 °C for 40 s, and extension at 72 °C for 50 s, followed by 72 °C for 7 min to complete the extension. Primer sequences were as follows: forward primer: CGGTCTTCAGAGAAGCCATT; reverse primer: GCAAAATCACATTATTGCCAAC. Direct sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The reactions were carried out using an ABI 3100 Genetic

---

Figure 1. Schematic representation of the immuno-wall device. (A) Immuno-wall chips with 40 microchannels (each 1 mm in width, 40 μm in height and 8.5 mm in length) in a cyclic olefin polymer substrate were constructed using photolithography. (B) The channels were filled with 6% azide-unit pendant water-soluble photopolymer (AWP) and 10 mg ml⁻¹ streptavidin. UV light (313 nm, 20 mW cm⁻²) through slits in a photomask was used to immobilize the photoactive polymer in the center of the channels, before the uncured polymer was washed with PBS. (C, D) A biotinylated anti-R132H-IDH1 antibody (HMab-2), an anti-wild-type IDH1 antibody (RcMab-1), and a fluorescent DyLight650-conjugated goat anti-rat IgG antibody were used to label IDH1-R132H.

Note that RcMab-1 is interacted with multiple numbers of DyLight 650-conjugated anti-rat IgGs.
Analyzer (Applied Biosystems). For pyrosequencing, we applied PCR at 50 cycles with denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s, and extension at 72 °C for 45 s, followed by 72 °C for 2 min to complete the extension. Primer sequences were as follows: forward primer: GGCTTGTGAGTGGATGGGTA; reverse primer: GGGACACCGCTGATCGTTATGTGTTGAATGAGCCTA and universal primer (5’-biotin) GGGACACCGCTGATCGTTA. Detection and calculation of the frequency of the mutant allele was performed using pyrosequencing technology (Pyrosequencing AB, Uppsala, Sweden) with the sequencing primer: TGGATGGGTAAACCTATCATCA, according to the manufacturer's instructions.[19]

2.8. Immunohistochemistry

HMab-2 antibody was used for immunohistochemistry. The tumor samples were fixed with 10% formalin and embedded with paraffin. Sections (5-μm thick) were prepared using a microtome (RM2125RT, Leica, Wetzlar, Germany). After deparaffinization and hydration, the sections were incubated in retrieval solution, Tris-EDTA buffer pH 9.0, for 30 min at 100 °C in an electric pot and then blocked with 1.5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) in PBS containing 0.05% Tween-20, at room temperature for 1 h, and were incubated with HMab-2, diluted to 1 μg ml⁻¹, overnight at 4 °C. The second labeled polymer from the EnVision HRP kit (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) was applied and the sections were incubated for 30 min. The substrate-chromogen solution from the DAB Substrate Kit (Vector Laboratories) was applied for 10 min. After washing, the sections were counterstained with hematoxylin and mounted in multi-Mount (Matsunami Glass Ind., Kishiwada, Japan).

2.9. Statistical analysis

The statistical significance of the differences between two cell line groups was determined using Student's t-test for the mean fluorescence intensity. P-values < 0.05 were considered significant.

3. Results

3.1. Sensitivity and specificity of immuno-wall assays

On the basis of our previous study which detected a mutation in lung cancer (manuscript in preparation), we found that 1.5 μl of cell lysate at a concentration of 1.0 mg ml⁻¹ was sufficient for conducting an immuno-wall assay. The cell lysate extracted from U87-IDH1-R132H, at a protein concentration of 0.5–2.5 mg ml⁻¹, yielded a positive fluorescence intensity along the immuno-wall (Figure S1). Thus, our device detected IDH1-R132H in as little as 0.5 mg ml⁻¹ of protein lysates.

Western blotting confirmed that the anti-IDH1-R132H antibody, HMab-2, was specific to the lysate from NHA-IDH1-R132H and U87-IDH1-R132H cells, whereas the anti-IDH1 antibody, RcMab-1, recognized both wild-type and mutant IDH1 in NHA and U87 cells (Figure 2(A)). In the immuno-wall assay, at the highest protein concentration (3.0 mg ml⁻¹), U87 and NHA cells expressing wild-type IDH1 did not show fluorescence while both types of cells expressing IDH1-R132H displayed strong fluorescence. The mean fluorescence intensity was significantly different between cells expressing wild-type IDH1 and IDH1-R132H (Figure 2(B)).

Next, in order to determine the detection limit of the ratio of mutated IDH1/wild-type IDH1, we mixed 3.0 mg ml⁻¹ cell lysate from mutant cells with the same concentration of wild-type cell lysate in various ratios. When mutated IDH1 comprised more than 10% of the cell lysate, strong fluorescence was observed. However, when the mutated cells accounted for less than 5% of the solution, fluorescence was difficult to distinguish from background intensity (Figure 3). The results indicate that the device can detect the IDH1-R132H mutation if the sample contains more than 10% of mutated IDH1. However, because the data shown here were determined using artificial cell lines overexpressing mutated or wild-type IDH1, further studies are needed to explore the detection threshold in clinical samples.

3.2. Patient characteristics and protein extraction from tumor samples

Next, we analyzed brain tumor samples to investigate the utility of our method in the clinical setting. We analyzed tumors from 10 patients (mean age, 47 ± 20, three males and seven females); three GBMs, four LGGs, one gliomatosis cerebri, and two non-gliomas (Table 1). The DNA sequencing showed that all four LGGs harbored the IDH1-R132H mutation. We lysed 5–14 mg tumor samples (mean weight: 9.6 mg) in 200 µl RIPA buffer. The lysates contained 1.8–3.5 (mean, 2.9 ± 0.5) mg ml⁻¹ of protein.

3.3. Immuno-wall assay of tumor samples

All four LGGs containing the IDH1-R132H mutation as determined by DNA sequencing displayed positive intensity in the immuno-wall assay. Next, we evaluated the mutant allele frequencies (MAFs) by pyrosequencing the LGG samples exhibiting the IDH1-R132H mutation (Table 1). A tumor sample with an MAF of 40% was selected, and its lysate was mixed with another lysate from a tumor with wild-type IDH1 such that the MAF was decreased stepwise from 40% to 20, 10, 5, 2, and 1%. Our immuno-wall assay for IDH1-R132H detected as low as 10% of MAF (Figure 4). The detection limit in clinical samples was consistent with that in cell lines.
3.4. Detection of tumor border with immuno-wall assay

As the immuno-wall was able to detect mutated cells with an MAF as low as 10%, we sought to utilize the device to estimate the gross tumor margin. A representative case of diffuse astrocytoma (Patient #8 in Table 1) is shown in Figure 5. During tumor removal surgery for this patient, two specimens were collected. A specimen from the center of the tumor showed positive intensity in the immuno-wall (Figure 5(A)), while, a specimen from the marginal region that appeared normal was negative (Figure 5(B)). The IDH1 status of these samples agreed with the immunohistochemistry and DNA sequencing results. These data demonstrate that our immuno-wall assay can guide surgeons to the boundary between the tumor and surrounding normal brain. The immuno-wall assay requires only 15 min, indicating that the assay can be used as an intraoperative modality to image the border between the tumor and normal brain.

4. Discussion

In this study, we established a highly sensitive antibody-based device to detect the IDH1-R132H mutation in glioma. Several techniques for detecting the IDH1 mutation were recently developed, such as modified PCR protocols.[20–23] Even the most rapid
Table 1. Patient characteristics and summarized results.

| Case no. | Age | Sex | Pathological diagnosis                        | Sample weight (mg) | Protein lysate concentration (mg ml\(^{-1}\)) | Amount of total protein (μg) | DNA sequencing | Immuno-wall | Mutant allele frequencies (%) |
|----------|-----|-----|-----------------------------------------------|--------------------|-----------------------------------------------|-----------------------------|----------------|--------------|-------------------------------|
| 1        | 30  | F   | Anaplastic astrocytoma (grade III glioma)     | 11                 | 2.71                                          | 542.4                       | Mut           | Mut          | 31.5                          |
| 2        | 53  | M   | Gliomatosis cerebri (grade III glioma)       | 7                  | 2.89                                          | 578.4                       | WT            | WT           | 0                             |
| 3        | 50  | F   | Diffuse astrocytoma (grade II glioma)        | 10                 | 3.47                                          | 694                         | Mut           | Mut          | 45.8                          |
| 4        | 78  | F   | Glioblastoma (grade IV glioma)               | 11                 | 2.69                                          | 538                         | WT            | WT           | 0                             |
| 5        | 19  | F   | Dysembryoplastic neuroepithelial tumor (DNT, non-glioma) | 9                 | 3.21                                          | 642.2                       | WT            | WT           | 0                             |
| 6        | 58  | F   | Pineal parenchyma tumor of intermediate differentiation (PPTID, non-glioma) | 5                 | 1.86                                          | 371.6                       | WT            | WT           | 0                             |
| 7        | 59  | M   | Glioblastoma (grade IV glioma)               | 10                 | 2.56                                          | 511.4                       | WT            | WT           | 0                             |
| 8        | 25  | F   | Anaplastic astrocytoma (grade III glioma)    | 12                 | 2.89                                          | 578.6                       | WT            | WT           | 0                             |
| 9        | 47  | M   | Glioblastoma (grade IV glioma)               | 14                 | 3.56                                          | 712.8                       | WT            | WT           | 0                             |
| 10       | 48  | M   | Diffuse astrocytoma (grade II glioma)        | 7                  | 2.35                                          | 470.2                       | Mut           | Mut          | 27.1                          |

Figure 4. Effect of the mutant allele frequency in clinical samples on the detection of mutated IDH1. The lysate from a tumor sample with a mutant allele frequency of 40% was mixed with the lysate from a tumor sample with wild-type IDH1 such that the mutant allele frequency decreased stepwise from 40% to 20, 10, 5, 2, and 1%. The immuno-wall assay IDH1-R132H detected the mutant allele frequency in samples containing as low as 10% mutant IDH1.

Our immuno-wall device was constructed using a high concentration of streptavidin (10 mg ml\(^{-1}\)) mixed with photoreactive polymer. Then primary antibody was immobilized to both sides of the walls via biotin–avidin binding. We estimated that the final density per area of primary antibody at the surface of the immuno-wall was approximately 0.155 μg mm\(^{-2}\) because the primary antibody was concentrated in the reaction with a high concentration of streptavidin during the 1-h incubation. We estimated the density of primary antibody at the bottom of the plate by using sandwich enzyme linked immunosorbent assay (ELISA; this method has high specificity) by using two antibodies and found a value of approximately 0.0014–0.0057 μg mm\(^{-2}\). Furthermore, fluorescence of the immuno-wall was integrated because the fluorescence signal extended laterally and all extended signals were observed from above. In contrast, the Western blotting signals were not integrated spatially because the membrane transfer signal was observed through a monolayer. A high density of primary antibody and integrated fluorescence increase the sensitivity of the immuno-assay compared to other immunoassays such as ELISA and Western blotting. Additionally, molecule movement is limited in the microchannels, enabling rapid detection because the primary antibody can capture molecules very quickly.

The rapid detection of IDH1 mutation may also assist in determining the extent of tumor removal. During a surgical resection of glioma, it is difficult to visually differentiate the tumor from the surrounding normal tissue. Intra-operative IDH1 profiling may be useful for detecting the border between the tumor and normal brain. In this study, we evaluated a representative LGG case in which IDH1-R132H was detected at the center of the tumor concurrent with wild-type IDH1 at the margin.

The emergence of molecular-targeting anti-cancer agents requires an individual molecular profiling of
tumors performed in a non-invasive manner. 'Precision medicine' for cancer patients trends toward sensitive analysis of circulating tumor cells or cell-free DNA in liquids such as blood and cerebrospinal fluid.[25,26] In this regard, the rapid molecular diagnostic method developed in this study may be an important milestone in precision medicine. In this study, we demonstrated that our immuno-wall assay could detect mutated IDH1 in a tissue lysate containing 10% IDH1 mutant allele at a protein concentration of 1.0–1.5 mg ml⁻¹ (Figure S2). Because the minimal sample volume for a microchannel is 0.33 μl, 500 ng protein or 500 cells is sufficient for determining IDH1 status. Total protein concentration in cerebrospinal fluid is more than 1.0 mg ml⁻¹ in patients with glioma.[27] Recent studies reported that the number of circulating tumor cells in the blood of glioma patients is approximately 10 cells ml⁻¹.[28,29] These suggest that there is a possibility that the IDH1 status can be determined with our device using cerebrospinal fluid and blood.

Some challenges remain before this diagnostic tool can be applied clinically, but our immuno-wall assay may lead to rapid and highly sensitive detection of the IDH1-R132H mutation preoperatively and intra-operatively. Clinical application, using a newly developed portable CCD camera, is currently under development; this will facilitate rapid on-site diagnosis. Our immuno-wall device will enable non-invasive rapid liquid biopsy in precision medicine.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
This work was supported by a JSPS KAKENHI [grant number 25462242]; Grant-in Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [grant number 23107010]; Practical Research for Innovation Cancer Control from Japan Agency for Medical Research and development, AMED; by ‘Knowledge Hub Aichi’, Priority Research Project from Aichi Prefectural Government; by the Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from AMED; and by the Regional Innovation Strategy Support Program from MEXT of Japan.

References
[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncology. 2014;16 Suppl 4, iv1-iv63.
[2] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.

[3] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.

[4] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466.

[5] Claus EB, Walsh KM, Wiencke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38:E6.

[6] Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genet. 2015;47:458–468.

[7] Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res: J Am Assoc Cancer Res. 2012;18:2490–2501.

[8] Hartmann C, Meyer J, Bals J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–474.

[9] Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Sci (New York, N.Y.). 2008;321:1807–1812.

[10] Arita H, Narita Y, Yoshida A, et al. IDH1/2 mutation detection in gliomas. Brain Tumor Pathol. 2015;32:79–89.

[11] Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125:621–636.

[12] Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–941.

[13] Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.

[14] Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773.

[15] Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.

[16] Kato Y, Jin G, Kuan CT, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun. 2009;390:547–551.

[17] Fujii Y, Ogasawara S, Oki H, et al. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochem Biophys Res Commun. 2015;466:733–739.

[18] Kato Y. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol. 2015;32:3–11.

[19] Shinjo K, Okamoto Y, An R, et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis. 2012;33:1277–1285.

[20] Kurimoto M, Suzuki H, Aoki K, et al. Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. Cancer Invest. 2016;34:12–15.

[21] Pang B, Durso MB, Hamilton RL, et al. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas. Diagn Mol Pathol: Am J Surg Pathol Part B. 2013;22:28–34.

[22] Horbinski C, Kelly L, Nikiforov YE, et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn JMD. 2010;12:487–492.

[23] Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119:501–507.

[24] Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg. 1997;86:525–531.

[25] Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239.

[26] Nayak, L, Fleisher, M, Gonzalez-Espinoza, R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80:1598–1605. discussion 1603.

[27] Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res. 2007;6:559–570.

[28] MacArthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014;74:2152–2159.

[29] Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4:1299–1309.